Mr Jeremy Riggle
Chief Scientist, Mary’s Medicinals and Mary’s Nutritionals, Denver, CO 80239, USA
Title: The potential role of cannabinoids in healing cosmetic products
Biography
Biography: Mr Jeremy Riggle
Abstract
The Endocannabinoid System (ECS), discovered at the end of the twentieth century, is a G-protein coupled receptor system involved in a number of physiological processes including pain sensation, metabolism, immunomodulation and inflammation. The ECS consists of cannabinoid receptor 1 (CB1), primarily found in the central nervous system, and cannabinoid receptor 2 (CB2), found predominantly in the lymphatic system. In addition to CB1 and CB2 receptors, there are also endocannabinoids and associated enzymes responsible for their synthesis and degradation that the body produces naturally. Phytocannabinoids have been found to modulate and influence ECS tone, with the two most well known compounds being D-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD). This receptor system, including the endocannabinoids and their synthesis/degradation enzymes, is also found in virtually all human skin cell types, indicating a significant role of the ECS in skin pathophysiology. In this presentation the potential role of phytocannabinoids for treating different skin conditions will be discussed. The challenges and obstacles to their use in cosmetic products, including regulatory hurdles, chemical compatibility issues, specific cannabinoids for certain indications and appropriate dosing will also be covered.